Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
This study is currently recruiting participants.
Verified February 2013
by Eisai Inc.
Study NCT01126749 Information provided by Eisai Inc.
First Received on May 17, 2010. Last Updated on February 27, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
Urinary Bladder Neoplasms
More general conditions related to this trial
Neoplasms by Site
Urinary Bladder Diseases
Interventions listed in this trial
gemcitabine plus cisplatin
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sponsors listed in this trial
PharmaBio Development Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers